3-(1-甲基环己基)-3-氧代丙腈 | 95882-32-9

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-(1-甲基环己基)-3-氧代丙腈
• 中文别名: 3-(1-甲基环己基)-3-酮基丙腈
• 英文名称: 3-(1-methylcyclohexyl)-3-oxopropanenitrile
• 英文别名: 3-(1'-methylcyclohexyl)-3-oxo-propiononitrile
• CAS: 95882-32-9
• 化学式: C₁₀H₁₅NO
• 分子量: 165.235
• InChiKey: OZHRTFVZNKBMRU-UHFFFAOYSA-N

物化性质

• 沸点：
  252.6±13.0 °C(Predicted)
• 密度：
  0.995±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  40.9
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2926909090

反应信息

• 作为反应物：
  描述：

  3-(1-甲基环己基)-3-氧代丙腈 以 四氢呋喃 、 甲苯 为溶剂， 生成 1-[5-(1-Methylcyclohexyl)-2-phenylpyrazol-3-yl]-3-phenylurea
  参考文献：
  名称：

  Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

  摘要：

  We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5'-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.

  DOI：

  10.1021/jm020057r
• 作为产物：
  描述：

  1-甲基环己烷羧酸 在 2,2'-联吡啶 、 正丁基锂 、 草酰氯 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 3.0h， 生成 3-(1-甲基环己基)-3-氧代丙腈
  参考文献：
  名称：

  Pyrazole Urea-Based Inhibitors of p38 MAP Kinase:  From Lead Compound to Clinical Candidate

  摘要：

  We report on a series of N-pyrazole, N'-aryl ureas and their mode of binding to p38 mitogen activated protein kinase. Importantly, a key binding domain that is distinct from the adenosine 5'-triphoshate (ATP) binding site is exposed when the conserved activation loop, consisting in part of Asp168-Phe169-Gly170, adopts a conformation permitting lipophilic and hydrogen bonding interactions between this class of inhibitors and the protein. We describe the correlation of the structure-activity relationships and crystallographic structures of these inhibitors with p38. In addition, we incorporated another binding pharmacophore that forms a hydrogen bond at the ATP binding site. This modification affords significant improvements in binding, cellular, and in vivo potencies resulting in the selection of 45 (BIRB 796) as a clinical candidate for the treatment of inflammatory diseases.

  DOI：

  10.1021/jm020057r

文献信息

• Novel indanylidene compounds
  申请人：——

  公开号：US20020143203A1

  公开（公告）日：2002-10-03

  Novel indanylidene compounds can be used as UV-A filters in cosmetic compositions for protecting skin and hair and for technical applications.

  新型吲哚亚甲基化合物可用作化妆品配方中的紫外A过滤剂，用于保护皮肤和头发以及技术应用。
• [EN] PYRAZOLE P38 MAP KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA MAP KINASE P38 À BASE DE PYRAZOLE
  申请人：RESPIVERT LTD

  公开号：WO2011121366A1

  公开（公告）日：2011-10-06

  There are provided inter alia compounds of formula (I): wherein R1, R2a, R2b, R3, R4, L, X, R5 and R6 are as defined in the description for use in the treatment of inflammatory diseases.

  其中提供了公式（I）的化合物：其中R1、R2a、R2b、R3、R4、L、X、R5和R6的定义如描述中所述，用于治疗炎症性疾病。
• PYRAZOLE P38 MAP KINASE INHIBITORS
  申请人：King-Underwood John

  公开号：US20130029990A1

  公开（公告）日：2013-01-31

  There are provided inter alia compounds of formula (I): wherein R 1 , R 2a , R 2b , R 3 , R 4 , L, X, R 5 and R 6 are as defined in the description for use in the treatment of inflammatory diseases.

  提供了公式（I）的化合物，其中R1、R2a、R2b、R3、R4、L、X、R5和R6如描述中所定义，用于治疗炎症性疾病。
• [EN] P38 MAP KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA MAP KINASE P38
  申请人：RESPIVERT LTD

  公开号：WO2011124930A1

  公开（公告）日：2011-10-13

  There is provided a compound of formula (I): wherein: J represents (A): or (B): compositions comprising same, processes for preparing said compounds and use thereof in treatment, particularly in the treatment of inflammatory disease, such as asthma, COPD and 15 rheumatoid arthritis.

  提供了一个化合物的公式（I）：其中：J代表（A）：或（B）：包括相同的组合物，制备该化合物的方法以及在治疗中的用途，特别是在治疗炎症性疾病，如哮喘、慢性阻塞性肺疾病和类风湿关节炎方面的用途。
• Novel Indanone Compounds
  申请人：Koch Oskar

  公开号：US20070185057A1

  公开（公告）日：2007-08-09

  Novel indanylidene compounds can be used as UV-A filters in cosmetic compositions for protecting skin and hair and for technical applications.

  新型的吲哚基烯化合物可以用作化妆品配方中的UV-A过滤剂，用于保护皮肤和头发，以及技术应用。